Temgicoluril

Temgicoluril, also known as tetramethylglycoluril, is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in Latvia and Russia under the brand names Mebicar and Adaptol.

As a pharmaceutical drug, its indications include the treatment anxiety, prevention and reduction of anxiety, unrest, fear, internal emotional tension and irritability, alleviation of the symptoms of neuroses and neurotic disorders, and heart pain of non-coronary heart disease origin. It is also used as adjunct treatment with neuroleptics for adverse effects management.

Its chemical structure makes it somewhat similar to uric acid, and while it doesn’t interact with acids, alkali, oxidants and reducing agents, it seems to affect all major neurotransmitter systems.

Temgicoluril is believed to exert its anxiolytic effects through modulation of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on several basic neuromediator systems – γ aminobutyric acid (GABA), serotonin, and adrenergic activity. It decreases brain norepinephrine levels and increases brain serotonin levels without direct effects on dopaminergic or cholinergic systems.

Unlike the typical anxiolytic medications such as benzodiazepines, it is non-habit forming, as its consumption does not result in intoxicating effects or euphoria and as such does not possess abuse potential. Furthermore, it does not produce muscle relaxation, motor function or memory impairment, as well as decreased activity or reaction time. Unless the rare side effects mentioned below are experienced, it should not interfere with driving, work related activities or learning. Its anxiolytic effects are not accompanied with sedation and translate into a clear-headed state, which accounts for its cognition enhancing properties, which is also why it could potentially be useful to alleviate the symptoms of ADHD.

While temgicoluril does not have a direct effect on sleep, it has been reported to enhances the effectiveness of sleep medicines and normalize the course of disturbed sleep. It is also known to alleviate or eliminate the symptoms of nicotine withdrawal.

It is important to note that despite its use does not lead to habituation or addiction, according to some sources, withdrawal syndrome is possible to occur upon its rapid use cessation.

Temgicoluril is orally bioavailable (77-80%), and is rapidly absorbed from the digestive system, achieving peak plasma concentrations in half an hour, with a plateau that lasts for for 3-4 hours, followed by a gradual dicrease. It is not metabolized and does not accumulate in human tissue.

Benefits of taking temgicoluril

• prominent anxiolytic effects;
• decreased irritability;
• calming effects without sedation;
• alleviated symptoms of neurotic disorders;
• enhanced focus and concentration;
• clear-headed mental state;
• better emotion regulation;
• aid in nicotine use cessation;
• possible aid in normalization of disturbed sleep.

Side effects

Temgicoluril is generally well-tolerated, and its adverse effects are relatively rare.

• dizziness;
• hypotension;
• indigestion;
• allergic reactions (skin rash, itching);
• hypothermia / body temperature decreased by 1 – 1.5 °C (high doses);
• fatigue (high doses).

Dosage

Temgicoluril is best taken without meals, initially at 500 mg 2-3 times daily, the upper limit at 3 g per single dose or 10 g per day. The treatment typically lasts from several days to 2-3 months.

In nicotine withdrawal management, it is usually dosed at 500 – 1000 mg three times per day over the period of 5-6 weeks.